Or les donnes disponibles suggrent que cette association dun agoniste de GLP-1 et dune autre hormone (GIP) aurait un effet sur la perte de poids encore plus important que le smaglutide
The 2023 study we mentioned earlier found some Ozempic users reported improved insomnia, anxiety, and depression
Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial)

This is probably related to the drugs incretin effect.20 The demonstrated potential of SEMA to reduce adipose accumulation at the lingual level may represent an additional mechanismbeyond weight lossfor improving the control of sleep apnoea.22 The SCALE programme also demonstrated the ability of LIRA 3 mg to improve cardiovascular risk factors (CVRFs), including blood pressure, lipid profile and inflammation markers.13 The effects on glycaemic control and CVRFs associated with SEMA 2.4 mg in the STEP programme are qualitatively similar, but quantitatively superior to those observed with LIRA 3 mg, possibly related to the different weight loss.16 The SELECT study, conducted with SEMA 2.4 mg, consistently showed a reduction of major adverse cardiac events (MACE) of triple composite endpoint (non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality) of 20% relative to placebo in a population with established cardiovascular disease and BMI greater than 27 kg/m2 without diabetes after 39.8 months of follow-up.23 Although a direct role of SEMA cannot be ruled out, the influence of adipose reduction and the improvement of adipocyte dysfunction probably contribute to the evolving profile of cardiovascular risk factors

If positive, this would provide the first direct evidence for using these drugs to treat inflammatory conditions
Another trial published in The Lancet in 2017 demonstrated that exenatide (Byetta) improved motor function in patients with Parkinson's disease, with some exploratory cognitive measures showing potential benefit, though the study was limited by small sample size and short duration